

Advancing Glucose Data Collection

IQVIA Connected Devices delivers more data with deeper insights

Technology advancements in continuous glucose monitoring (CGM) used for research and treatment of both Type 1 and Type 2 Diabetes are rapidly increasing. **IQVIA Connected Devices** is modernizing clinical development with industry-leading innovation to drive faster and increased data collection, with a better patient-centric experience, by collecting a more complete and dynamic view of the daily measures of glucose levels and variability than traditional measures of glucose control by self-monitored blood glucose (SMBG) and Hemoglobin A1c (HbA1c).

Our eSource technology and portfolio of digital and connected CGM solutions work together to mitigate risk and consolidate, verify and analyze continuous bi-directional data flow, all in a centralized view within our **Connected Devices Digital Platform**.

Dedicated and proven diabetes expertise

USE CGM CONNECTED DEVICES TO ENRICH YOUR STUDY WITH CONNECTIONS THAT COUNT

 **Providing CGM and connected devices support for clinical trials** since 2016

>200 diabetes Phase I-IV clinical studies since 2011 

 **IQVIA has provided >23K CGM devices to support clinical development in 36 countries** since 2016



Your challenges

TIME CONSTRAINTS

- HbA1c testing requires 8-12 weeks of time in trial to deliver glucose level trends and insights
- An SMBG device is dependent on patient compliance and the standard is 4-7 readings per day
- Regulatory requirements lead to larger and longer trials

DATA QUALITY LIMITATIONS

- HbA1c is unable to indicate intraday variations in glucose levels
- HbA1c does not allow a site/sponsor to ensure safety or accurately review glucose Time in Range (TIR) data
- SMBG is only capable of providing a static "point in time" data point for blood glucose levels
- Blood glucose levels can vary widely during the time between SMBG readings

INCREASED BURDEN

- Intermittent fingerstick testing using SMBG is highly burdensome and provides inadequate data for decision-making guidance
- Sites and sponsors are dependent on patient compliance to make informed decisions to impact trial effectiveness
- 8-12 weeks of required engagement by the patient

Our solution

IQVIA Connected Devices delivers an innovative approach to advance CGM data collection and insights used to enhance safety and the impact of clinical outcomes through:

ACCELERATED CLINICAL DEVELOPMENT

- Reduces clinical development timelines by delivering faster access to continuous data collection and analysis
- Always on, connected data streaming provides a single, robust view of a patient's glycemic control, alleviating the need for 8-12 weeks of continuous engagement
- Real-time data monitoring provides deeper insights leveraged to inform current and future therapy choices


ROBUST DATA COLLECTION

- Access to deeper insights faster with a holistic view of the patient's glycemic control over a defined period of time and in-house statistical analysis offered by Connected Devices
- Delivers up to 288 readings per day allowing data to be evaluated at specific points to easily determine TIR
- SMBG and CGM data results support primary and secondary protocol endpoints, offering a detailed look at patient control, in addition to HbA1c reduction

REDUCED BURDEN AND IMPROVED EXPERIENCE

- Offers patients the ability to insert the CGM wearable device by themselves at home, allowing them to choose their path to treatment
- Delivers superior safety endpoints for studies where glycemic control is the focus
- Proven, robust device portfolio and expertise with a commitment to global regulatory compliance to ease study start-up and reduce site, sponsor and patient burdens
- Enables a faster response to blood glucose excursions that may otherwise result in severe hypoglycemic or hyperglycemic events
- Simplifies site and investigator experience with streamlined workflows and reduced data entry

The ecosystem of blood glucose management incorporating continuous glucose monitoring



Source: IQVIA, Aug 2019

Discover how IQVIA Connected Devices can help enhance clinical trials focused on the positive impacts of glycemic control through advanced CGM technologies.



CONTACT US
iqvia.com/connecteddevices